华源证券研报指出，新和成产品线持续拓宽，业绩韧性十足。蛋氨酸快速放量，成本优势明显。据博亚 和讯统计，全球蛋氨酸需求保持4-6%左右增长，需求增量约10万吨/年。蛋氨酸供给集中，赢创、安迪 苏等CR4市场份额超80%。装置老化、成本上升等因素导致海外龙头份额持续收缩，去年8月宁夏紫光 天化蛋氨酸有限责任公司以7.74亿挂牌拟出售。公司现有产能55万吨，跃居全球前列。公司成本优势明 显，24年和25年上半年山东新和成氨基酸有限公司净利率分别为35%/38.3%。此外，香料盈利能力较 强，持续稳定增长，新材料有望快速增长。需求旺季及反内卷政策推动，近期维生素和蛋氨酸价格均企 稳回升。选择安迪苏、浙江医药、金达威作为可比公司，考虑到公司是全球精细化工龙头之一，兼具产 品涨价弹性及新材料未来成长性，首次覆盖，给予"买入"评级。 ...

截至2026年2月26日 13:57，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 3.63%，兴齐眼药上涨2.61%，爱博医疗上涨2.28%；惠泰医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近3天获得连续资金净流入，最高单日获得617.32万元净流入， 合计"吸金"1269.71万元，日均净流入达423.24万元。（数据来源：Wind） 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 数据显示，截至2026年1月30日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、迈瑞医疗、恒瑞医药、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.9%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈 ...

证券研究报告 晨会 hyzqdatemark 2026 年 02 月 25 日 投资要点： | 市场数据 指数名称 | 收盘价 | 涨跌幅 | 年初至今 | | --- | --- | --- | --- | | 上证指数 | 4,147.23 | 0.72% | 3.08% | | 创业板指 | 3,354.82 | 1.41% | 1.83% | | 沪深 300 | 4,735.89 | 0.60% | 0.38% | | 中证 1000 | 8,426.33 | 1.52% | 8.67% | | 科创 50 | 1,473.28 | 0.54% | 4.98% | | 北证 50 | 1,547.20 | 0.77% | 5.51% | 资料来源：聚源，华源证券研究所，截至2026年02月25日 华源晨会精粹 20260225 固定收益 25Q4 保险公司资金运用有何变化？根据国家金融监督管理总局数据，截 至 25Q4，保险公司资金运用余额共计 38.48 万亿元，较 25Q3 增长 2.71%。截至 25Q4 险资（财产险及人身险公司，下同）债券投资余额同比增长 17.43%，其中 25Q4 单季 ...

证券研究报告 基础化工 | 化学制品 非金融|首次覆盖报告 证券分析师 hyzqdatemark 2026 年 02 月 25 日 李辉 SAC：S1350526010001 lihui01@huayuanstock.com 张峰 SAC：S1350525120003 zhangfeng03@huayuanstock.com 李佳骏 SAC：S1350526010004 lijiajun@huayuanstock.com 市场表现： | 基本数据 | | | | 2026 | 年 | 02 | 月 24 | 日 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | 29.59 | | | 一 年 内 最 低 | 最 | 高 | / | | | | 30.99/19.52 | | | （元） | | | | | | | | | | 总市值（百万元） | | | | | | | 90,942.55 | | | 流通市值（百万元） | | | | | | | 89,860.74 | | | 总股本（百万股） ...

内容概要：随着生猪养殖、家禽养殖、水产养殖规模化、集约化程度持续提升，配合饲料市场渗透率不 断提高，蛋氨酸作为畜禽水产生长发育的必需氨基酸，是饲料配方中不可替代的核心添加剂，饲料领域 市场需求随之稳步攀升，与此同时，蛋氨酸在食品营养强化、医药氨基酸输液、保健品、日化原料等非 饲料领域的应用场景持续拓宽，非饲料端需求快速增长，打破行业长期单一依赖养殖产业的格局，多元 需求结构逐步形成，不仅有效平抑行业周期性波动风险，更为产业发展打开全新增长空间，据统计， 2025年我国蛋氨酸需求量达40.9万吨，同比增长3.6%；全年产量完成54.6万吨，同比增长10.3%。 上市企业：新和成（002001）、和邦生物（603077）、安迪苏（600299） 相关企业：赢创（中国）投资有限公司、住友化学（上海）有限公司、希杰（中国）咨询有限公司、宁 夏紫光天化蛋氨酸有限责任公司、河北华阳生物科技有限公司 关键词：蛋氨酸行业相关政策汇总、蛋氨酸产业链图谱、蛋氨酸供需现状、蛋氨酸进出口贸易、蛋氨酸 竞争格局、蛋氨酸发展趋势 一、概述 蛋氨酸，学名甲硫氨酸（Methionine，缩写Met/M），是含硫的必需氨基酸，人体及动物自身无 ...

Investment Rating - The report maintains a "Positive" rating for the chemical industry [4][3]. Core Insights - The macroeconomic outlook for the chemical industry indicates a stable increase in oil demand due to global economic recovery and tariff adjustments, with Brent crude oil expected to remain in the range of $60-75 per barrel [4][5]. - The report highlights a potential spring boom in the chemical sector, driven by the success of domestic robotics showcased during the Spring Festival and favorable export conditions following tariff reductions [4][3]. - Investment opportunities are identified in various chains, including textiles, agricultural chemicals, and overseas real estate, with specific companies recommended for investment [4][3]. Industry Dynamics - Oil supply is tightening due to OPEC+ production delays and peak shale oil output, while demand is stabilizing with improved global economic conditions [5]. - The chemical industry is at a cyclical turning point, with downstream operations gradually resuming post-holiday, indicating a positive demand outlook for the year [4][3]. - The report notes that the Producer Price Index (PPI) for industrial products decreased by 1.4% year-on-year in January, while the manufacturing PMI recorded 49.3, indicating some volatility in manufacturing activity [7][4]. Investment Analysis - The report suggests a diversified investment strategy focusing on four key areas: textiles, agricultural chemicals, export chains, and beneficiaries of "anti-involution" policies [4][3]. - Specific companies to watch include those in the textile chain like Lu Xi Chemical and Tongkun Co., and in the agricultural chain like Hualu Hengsheng and Baofeng Energy [4][3]. - The report emphasizes the importance of self-sufficiency in key materials, particularly in semiconductor and panel materials, recommending companies such as Yake Technology and Ruilian New Materials [4][3].

Group 1 - In 2025, China's foreign trade showed strong resilience, with total exports reaching a historical high, growing by 5.5% year-on-year, despite a complex external environment [1][57] - China's trade surplus exceeded $1 trillion for the first time, marking a significant increase of 19.8% year-on-year [1][57] - The net export of goods and services contributed 1.64 percentage points to GDP growth, the second-highest level since 2007, only behind 2021 [3] Group 2 - The diversification of external demand has strengthened, with emerging markets compensating for the decline in exports to the US, which fell by 19.79% year-on-year [6] - Exports to ASEAN, Africa, and the Middle East saw significant growth rates of 25.9%, 13.64%, and 9.7% respectively, contributing positively to the overall export scale [6] - The share of US exports in China's total exports decreased by 3.53 percentage points to 11.15% [6] Group 3 - The product structure of China's foreign trade is shifting towards higher value chains, with high-end products like electrical machinery, machinery, automobiles, and ships being the main export drivers [8] - Traditional light industrial products such as furniture and toys have seen a decline in export scale due to tariff friction and industrial chain relocation [8] Group 4 - The restructuring of global supply chains is creating significant opportunities for Chinese companies, with a notable increase in the number of Chinese enterprises establishing production capacities abroad, reaching 229 in 2025, nearly doubling from 2024 [18] - ASEAN, Mexico, and India are the primary destinations for Chinese production capacity outflows, with ASEAN covering a wide range of industries [18] Group 5 - The AI expansion cycle is a core focus in the Chinese capital market, with significant growth expected in AI computing hardware, supported by macro investment scales and healthy balance sheets of major tech companies [29][30] - The capital expenditure of major cloud service providers is projected to increase significantly, reflecting strong demand for AI computing [35] Group 6 - Cultural and technological value output is becoming a major trend for Chinese enterprises going abroad, with significant growth in IP exports and innovative products in sectors like gaming and new dining [39][41] - The Chinese innovative pharmaceutical sector is increasingly integrated into the global supply chain, with more products commercialized in the US and Europe [41] Group 7 - Key sectors with strong overseas expansion opportunities in 2026 include new energy (batteries, grid equipment), machinery, TMT (technology, media, telecommunications), and innovative pharmaceuticals [46] - The gaming industry is also highlighted for its potential, with significant overseas revenue growth expected [49]

证券日报网讯 2月12日，新和成（002001）在互动平台回答投资者提问时表示，公司产品的原料耗量属 于技术秘密，公司将持续优化工艺技术，提升生产运营效率。 ...

Industry Overview - Peptides are bioactive fragments of proteins that can be rapidly absorbed and utilized by the human body, providing energy and nutrients to cells. Their potential has been further released since the Human Genome Project in the 1990s, leading to unprecedented prosperity in peptide research and applications, especially in the pharmaceutical field [1][13] - The Chinese peptide industry market size is projected to grow from 57.34 billion yuan in 2016 to 209.12 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.56%. By 2025, the market size is expected to reach approximately 247.6 billion yuan [1][13] Market Segmentation - The peptide industry value chain consists of upstream raw materials and equipment (amino acids, amino acid protectants, resin acids, synthesis instruments, packaging materials), midstream production and manufacturing, and downstream applications in food, pharmaceuticals, feed, health products, and cosmetics [9][11] - The global peptide drug market is expected to reach approximately 96 billion USD by 2025, driven by the increasing prevalence of chronic diseases and the unique advantages of peptide drugs in treatment [12][17] Key Companies - HanYue Pharmaceutical focuses on four main areas: peptide formulations, raw materials, small nucleic acids, and CRDMO services. The company has achieved significant revenue growth, with a reported 114.86% increase in pharmaceutical manufacturing revenue in the first half of 2025 [20][21] - ZhongPeptide Biochemical Co., Ltd. specializes in contract research, development, and production of peptides and small nucleic acids, providing comprehensive services from early discovery to commercial production [21] Development Trends - The Chinese peptide industry is transitioning from traditional chemical synthesis to a deep integration of biotechnology and synthetic biology, enhancing production efficiency and reducing costs [22][24] - The application of peptides is rapidly expanding beyond pharmaceuticals into health, beauty, and functional food markets, with increasing consumer demand for personalized health solutions [23][24] - The industry is also moving towards green manufacturing and sustainable development, focusing on reducing environmental footprints and enhancing social responsibility [24]

Group 1 - The core viewpoint of the article highlights that the domestic ex-factory price of erythritol in the United States is considered non-public commercial information and is typically higher than that of Chinese export products due to local energy, labor, and raw material costs [1] - The company will continue to monitor global price trends and aims to maintain its core competitiveness through technological innovation and cost optimization in response to changes in the international trade environment [1]